(+)-UH 232, a partial agonist of the D3 dopamine receptors, attenuates cognitive effects of angiotensin IV and des-Phe6-angiotensin IV in rats

European Neuropsychopharmacology

Volumn 20, Issue 4, 2010, Pages 218-225

  Braszko, Jan J ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

(+) UH 232; Angiotensin IV; Des Phe6 angiotensin IV; Dopamine D3 receptor; Memory; Rat; Stereotype behaviour

Indexed keywords

2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; ANGIOTENSIN II [3-8]; ANGIOTENSIN IV [6 DESPHENYLALANINE]; APOMORPHINE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SELECTIVITY; EMOTION; LOCOMOTION; LOW DRUG DOSE; MALE; MAZE TEST; MENTAL TEST; MOTOR PERFORMANCE; NONHUMAN; OPEN FIELD TEST; PASSIVE AVOIDANCE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RAT; RECALL; STEREOTYPY; WISTAR RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANGIOTENSIN II; ANIMALS; APOMORPHINE; AVOIDANCE LEARNING; COGNITION; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG PARTIAL AGONISM; EXPLORATORY BEHAVIOR; MALE; MAZE LEARNING; RATS; RECEPTORS, ANGIOTENSIN; RECEPTORS, DOPAMINE D3; RECOGNITION (PSYCHOLOGY); STEREOTYPED BEHAVIOR;

EID: 77349089701     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.11.012     Document Type: Article

References (41)

1. Ader R., Weijnen J.A.W.M., and Moleman P. Retention of a passive avoidance responses as a function of the intensity and duration of electric shock. Psychon. Sci. 26 (1972) 125-129
2. 4) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 276 (2001) 48623-48626
3. Barik S., and de Beaurepaire R. Dopamine D3 modulation of locomotor activity and sleep in the nucleus accumbens and in lobules 9 and 10 of the cerebellum in the rat. Prog. Neuro-Psychopharm. Biol. Psychiatr. 29 (2005) 718-726
4. 6 angiotensin IV. Peptides 25 (2004) 1195-1203
5. 6-Ang IV. Physiol. Behav. 88 (2006) 152-159
6. Braszko J.J. Dopamine D4 receptor antagonist L745, 870 abolishes cognitive effects of intracerebroventricular angiotensin IV and des-Phe6-Ang IV in rats. Eur. Neuropsychopharmacol. 19 (2009) 85-91
7. Braszko J.J., Walesiuk A., and Wielgat P. Cognitive effects attributed to angiotensin II may result from its conversion to angiotensin IV. J. Renin. Angiotensin Aldosterone Syst. 7 (2006) 168-174
8. 3 dopamine receptors blockade on the cognitive effects of angiotensin IV in rats. Neuropeptides 42 (2008) 301-309
9. Braszko J.J., Wiśniewski K., Kupryszewski G., and Witczuk B. Psychotropic effects of angiotensin II and III in rats: locomotor and exploratory vs. cognitive behaviour. Behav. Brain Res. 25 (1987) 195-203
10. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Ann. Rev. Pharmacol. Toxicol. 41 (2001) 237-260
11. A receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens. J. Neurosci. 26 (2006) 2513-2521
12. 125I]Ang IV binding and catalytic activity. Biochem. Pharmacol. 68 (2004) 885-892
13. Droste D.W., Ritter M.A., Dittrich R., Heidenreich S., Wichter T., Freund M., and Ringelstein E.B. Arterial hypertension and ischaemic stroke. Acta Neurol. Scand. 107 (2003) 241-251
14. Du F., Li R., Huang Y., Li X., and Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur. J. Neurosci. 22 (2005) 2422-2430
15. Ennaceur A., and Meliani K. A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs nonspatial working memory. Behav. Brain. Res. 51 (1992) 83-92
16. Gard P.R. Cognitive-enhancing effects of angiotensin IV. BMC Neurosci. 9 Suppl 2 (2008) S15 10.1186/1471-2202-9-S2-S15
17. de Gasparo M., Catt K.J., Inagami T., Wright J.W., and Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52 (2000) 415-472
18. Gavras, H., Brunner, HR. (2001) Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure. Hypertension 37, 342-345.
19. 3 receptor ligand, (+)-UH 232, is a partial agonist. Eur. J. Pharmacol. 282 (1995) R3-R4
20. Harding J.W., Cook V.I., Miller-Wing A.V., Hanesworth J.M., Sardinia M.F., Hall K.L., Stobb J.W., Swanson G.N., Coleman J.W., and Wright J.W. Identification of an AII(3-8) [AIV] binding site in guinea pig hippocampus. Brain Res. 583 (1992) 340-343
21. 3 receptor is part of a homeostatic pathway regulating ethanol consumption. J. Neurosci. 26 (2006) 1457-1464
22. Kennedy L.A., and Zigmond M.J. The behavioural effects of D-amphetamine are correlated with its effects on cAMP in different brain regions. Brain Res. 168 (1979) 408-413
23. Kothari S.A., Le M.K., and Gandhi P.J. Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications. J. Thromb. Thrombolysis 15 (2003) 217-225
24. 3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J. Neural. Transm. 105 (1998) 719-734
25. Le M.T., Vanderheyden P.M.L., Szaszak M., Hunyady L., and Vauquelin G. Angiotenisin IV is a potent agonist for constitutive active human AT1 receptors: distinct roles of the N- and C-terminal residues of angiotensin II during AT1 receptor activation. J. Biol. Chem. 277 (2002) 23107-23110
26. 2 dopamine receptor. Brit. J. Pharmacol. 149 (2006) 291-299
27. 256 of AT1 receptor in agonist activation. J. Biol. Chem. 270 (1995) 28511-28514
28. Pellow S., Chopin P., and Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14 (1985) 149-167
29. Randrup A., and Munkvad I. Pharmacology and physiology of stereotyped behaviour. J. Psychiatr. Res. 11 (1974) 1-10
30. 4 receptor binding characteristics: D-amino acid- and glycine-substituted peptides. Peptides 14 (1993) 949-954
31. Sleight P. The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension. Curr. Cardiol. Rep. 3 (2001) 511-518
32. 3) as a target for neuroleptics. Nature 347 (1990) 146-151
33. Stragier B., Sarre S., Vanderheyden P., Vauquelin G., Fournie-Zaluski M.C., Ebinger G., and Michotte Y. Metabolism of angiotensin II is required for its in vivo effect of dopamine release in the striatum of the rat. J. Neurochem. 90 (2004) 1251-1257
34. Stragier B., Demaegdt H., de Bundel D., Smolders I., Sarre S., Vauquelin G., Ebinger G., Michotte Y., and Vanderheyden P. Involvement of insulin-regulated aminopeptidase and/or aminopeptidase N in the angiotensin IV-induced effect on dopamine release in the striatum of the rat. Brain Res. 1131 (2007) 97-105
35. Stragier B., Hristova I., Sarre S., Ebinger G., and Michotte Y. In vivo characterization of the angiotensin-(1-7)-induced dopamine and γ-aminobutyric acid release in the striatum of the rat. Eur. J. Neurosci. 22 (2005) 658-664
36. Strange P.G. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol. Sci. 29 (2008) 314-321
37. Svensson K., Johansson A.M., Magnusson T., and Carlsson A. (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn-Schmiedeberg's Arch. Pharmacol. 334 (1986) 234-245
38. Wright J.W., Yamamoto B.J., and Harding J.W. Angiotensin receptor subtype mediated physiologies and behaviours: new discoveries and clinical targets. Prog. Neurobiol. 84 (2008) 157-181
39. 3 receptor stimulation in the induction of neurogenesis in the adult rat substantia nigra. Neuroscience 136 (2005) 381-386
40. 3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology 50 (2004) 305-310
41. Xi Z.-X., Gilbert J., Campos A.C., Kline N., Ashby Jr. Ch.R., Hagan J.J., Heidbreder Ch.A., and Gardner E.L. Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology 176 (2004) 57-65